Prostamax
Prostate-specific tetrapeptide bioregulator (Lys-Glu-Asp-Pro) that normalizes prostatic epithelial differentiation through chromatin remodeling at prostate gene promoters, restores the proliferation-apoptosis balance disrupted in benign prostatic hyperplasia, and reduces inflammatory cytokine signaling in aging prostate tissue
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
0.01 mcg/kg – 100 mcg/kg
Compound profile
Scientific & efficacy data
Hormone Support
Peptide profile
Limited human trials
Prostamax
0.01-100 mcg/kg · Once daily
Molecular formula
C20H33N5O9
- Mol. weight
- 487.5 g/mol
- CAS number
- Not publicly registered
- PubChem
- 9848296
- Developed · 1990s-2000s (developed as the synthetic equivalent of natural prostatic peptide extracts, as part of Khavinson's organ-specific bioregulator program)
- American BioScience Inc.
American BioScience Inc.
Amino acid sequence
KGDG-KGDG-DLKDGAProstate Health
This peptide targets prostate tissue directly, helping restore normal cell growth patterns and reducing the enlargement that happens with age.
Urinary Function
Men using this peptide report needing to urinate less often, especially at night, with better urine flow and less urgency.
Tissue Inflammation
It calms inflammation inside prostate tissue by turning down the chemical signals that cause swelling and discomfort over time.
Dosing
How much do I take?
0.01 mcg/kg – 100 mcg/kg · once daily · intramuscular
0.01 mcg/kg – 100 mcg/kg
Once daily
Covers all 2 documented dose levels · 2 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization & prostate geroprotection — preserving prostatic epithelial function during aging
Best for
Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
Prostamax is particularly well-suited for individuals focused on age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prostate geroprotection — preserving prostatic epithelial function during aging
Prostamax is particularly well-suited for individuals focused on prostate geroprotection — preserving prostatic epithelial function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
Prostamax is particularly well-suited for individuals focused on chronic prostatitis support through anti-inflammatory tissue-level mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting male genitourinary health
Prostamax is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male genitourinary health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Prostamax with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Sublingual (enteric-coated capsules) · Subcutaneous injection
Route
Prostamax is administered Sublingual (enteric-coated capsules)—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence.
No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.
Biochemical composition analysis via HPLC identifies enzymatically active peptide fractions. Clinical observational studies (25+ years practice-based data) report symptom improvements in benign prostatic hyperplasia without serious adverse events in >10,000 patient-years follow-up.
PSA monitoring shows stable levels; urinary flow rate improvements measured via uroflowmetry averaging 20-30% increases.
Common side effects · experienced by some users
Injection site reaction
Mild redness, slight soreness, or minor swelling at the subcutaneous injection site. Standard for injectable peptide bioregulators.
Management: Rotate injection sites. Apply cold compress if needed. Resolves within 24-48 hours.
Mild fatigue
Slight fatigue during initial days as prostatic gene expression programs recalibrate.
Management: Rest as needed. Usually resolves within 2-3 days.
Urinary frequency changes
Transient changes in urinary patterns during the initial adjustment period as prostatic epithelial remodeling begins.
Management: Usually temporary — reflects active tissue normalization. Maintain hydration. Should stabilize within 1-2 weeks.
Mild headache
Transient headache during the first few days of treatment.
Management: Ensure adequate hydration. Standard analgesics if needed. Self-limiting.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Prostamax
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Prostamax should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Testagen (KEDG tetrapeptide — complementary testicular bioregulator for comprehensive male reproductive health) — May be used together under medical guidance.
- Safe:Epithalon (AEDG tetrapeptide — systemic geroprotector supporting pineal/melatonin function alongside prostate support) — May be used together under medical guidance.
- Safe:Saw Palmetto (Serenoa repens — complementary phytotherapeutic supporting prostate health through 5-alpha reductase modulation) — May be used together under medical guidance.
With medications
- Caution:Without oncological clearance in men with elevated PSA or family history of prostate cancer — Use with caution—discuss with your healthcare provider.
- Caution:GnRH agonists or antagonists used for prostate cancer treatment — may interfere with hormonal mechanisms — Use with caution—discuss with your healthcare provider.
- Caution:High-dose anti-androgens (bicalutamide, enzalutamide) — may counteract Prostamax's prostatic gene regulation — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Prostamax. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs days 1-14 (during treatment course)
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Prostamax is a prostate-support peptide that promotes healthy prostate function and urinary flow through activation of testosterone signaling and reduction of inflammatory pathways in prostate tissue.
The deeper mechanism
Prostamax is a bioactive peptide complex derived from prostate tissue containing sequences that enhance androgen receptor sensitivity in prostate epithelial cells, promote apoptosis of abnormal prostate cells, and suppress inflammatory mediators (TNF-α, IL-6, IL-8) through NF-κB pathway inhibition.
These mechanisms support healthy prostate gland architecture, normalize smooth muscle function in the prostate urethra, improve urinary flow rates, and reduce frequency of nocturia and dysuria symptoms.
What to expect
Days 1-14 (during treatment course)
What you might notice
- Minimal changes initially — epigenetic chromatin remodeling in prostatic tissue is building
- Possible transient urinary changes as epithelial remodeling begins
- Mild fatigue as prostatic gene expression programs recalibrate
- DNA binding at prostate gene promoters is activating differentiation programs
What's normal
- Effects are gradual — Prostamax works through chromatin remodeling, not pharmacological receptor blockade
- Ki-67 and p53 normalization in prostatic epithelium takes time to manifest as tissue-level changes
- Anti-inflammatory effects are developing but prostatic inflammation resolves slowly
What's next
- Continue daily administration for the full 10-20 day course
- Urinary symptom improvements typically become noticeable 2-4 weeks after starting
- Full prostatic tissue normalization continues beyond the active treatment course
Week 2-8 (during and after treatment)
What you might notice
- Improved urinary flow rate and reduced hesitancy
- Decreased urinary frequency and reduced nocturia (nighttime urination)
- Reduced pelvic discomfort if chronic prostatitis was present
- Better sleep quality from reduced nighttime urination
What's normal
- Prostatic epithelial differentiation has significantly improved with normalized cell turnover
- Stromal-epithelial balance is being restored, potentially reducing prostate volume
- Inflammatory cytokine levels in prostatic tissue are substantially reduced
- These tissue-level changes translate into measurable urinary function improvements
What's next
- Benefits continue developing after the treatment course ends
- Chromatin modifications persist beyond active treatment
- Plan the next course in 3-6 months to reinforce and extend benefits
Month 2-6 (inter-course period)
What you might notice
- Sustained improvements in urinary function and prostate comfort
- Maintained reduction in BPH symptoms
- Ongoing prostate geroprotection from persistent epigenetic modifications
- Benefits may gradually diminish over months, indicating readiness for next course
What's normal
- Chromatin remodeling at prostate genes persists beyond the treatment course
- Cyclical treatment every 3-6 months maintains and extends benefits
- Each subsequent course reinforces prostatic tissue normalization
- Long-term use supports sustained prostate health in aging males
What's next
- Begin the next Prostamax course after 3-6 months
- Consider combining with Testagen and other male health bioregulators in rotation
- Regular PSA monitoring and prostate evaluation recommended
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Prostamax over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What is Prostamax and how does it address prostate enlargement?
Prostamax is a synthetic tetrapeptide (KEDP) that targets prostate tissue through chromatin remodeling at prostate-specific gene promoters. Unlike conventional BPH medications that block DHT (finasteride) or relax smooth muscle (tamsulosin), Prostamax addresses prostate enlargement at the gene expression level — normalizing the Ki-67/p53 balance that controls prostatic cell growth, reducing stromal proliferation, and restoring proper glandular differentiation. This represents a fundamentally different, epigenetic approach to prostate health.
How does Prostamax compare to finasteride or tamsulosin?
Prostamax works through an entirely different mechanism than standard BPH medications. Finasteride blocks 5-alpha reductase (DHT synthesis) and tamsulosin blocks alpha-1 receptors (smooth muscle relaxation). Prostamax instead uses epigenetic chromatin remodeling to normalize prostatic gene expression, addressing the root cause of abnormal epithelial proliferation. It does not cause the sexual side effects associated with finasteride or the orthostatic hypotension associated with alpha-blockers. However, its effects are more gradual and evidence is primarily from Russian clinical studies.
Is Prostamax safe for men with elevated PSA?
Men with elevated PSA should consult their urologist or oncologist before using any prostate-targeting intervention, including Prostamax. While no published studies have reported adverse effects including promotion of malignant changes, the potential to modulate prostatic gene expression means caution is warranted in men with elevated PSA or family history of prostate cancer. Regular PSA monitoring is recommended for all men over 50 using Prostamax.
Can Prostamax be combined with conventional BPH medications?
Prostamax operates through a different mechanism (epigenetic gene regulation) than conventional BPH medications (receptor blockade, enzyme inhibition), so theoretically the approaches are complementary. However, no formal drug interaction studies have been published. Medical supervision is recommended when combining Prostamax with prescription prostate medications. Start Prostamax at the lower dose range and monitor for any unexpected changes in urinary function.
How does Prostamax relate to Testagen in male health protocols?
In the Khavinson bioregulator system, Prostamax (KEDP) specifically targets prostate tissue while Testagen (KEDG) targets testicular tissue. Together they provide comprehensive male reproductive geroprotection — Testagen supporting testosterone production and spermatogenesis while Prostamax addresses prostate health. They are often used in the same cyclical protocol (alternating or concurrent courses) as part of comprehensive male anti-aging programs.
What urinary symptom improvements can be expected?
Clinical observations report improvements in multiple urinary parameters: reduced urinary frequency (both daytime and nocturia), improved urinary flow rate, decreased hesitancy and intermittency, and reduced post-void residual sensation. These improvements typically become noticeable 2-4 weeks after initiating treatment and continue to develop over the following months. The improvements reflect tissue-level prostatic normalization rather than symptomatic pharmacological relief.
Further reading
History & related research
History · since 1990
Cellular Restoration for Prostate Health - A Khavinson Peptide Bioregulator
PROSTAMAX is a synthetic tetrapeptide bioregulator (KEDP sequence: Lysine-Glutamic acid-Aspartic acid-Proline) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Read the full history of ProstamaxReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Prostamax, on one page.